Viral Hepatitis

Quick Links

Veterans Crisis Line Badge
My healthevet badge

Management and Treatment of Hepatitis C Viral Infection: Table 6

for Health Care Providers

Table 6. Comparison of Sustained Virologic Response (SVR) Rates for Peginterferon Alfa-2a Combination Therapy, Peginterferon Alfa-2a Monotherapy, and Interferon Alfa Combination Therapy Given Over 48 wk

Back to Therapy for Previously Untreated Patients

*peginterferon alfa-2a 180 mcg/week plus ribavirin 1,000 or 1,200 mg/day

peginterferon alfa-2a 180 mcg/week plus placebo

IFN 3 million U three times/week plus ribavirin 1,000 or 1,200 mg/day

§Compared to interferon alfa plus ribavirin

**Defined as >2 million copies/mL (COBAS AMPLICOR HCV Test, v. 2.0, sensitivity 100 copies/mL); equivalent to >800,000 IU/mL

Defined as ≤2 million copies/mL (COBAS AMPLICOR HCV Test, v. 2.0, sensitivity 100 copies/mL); equivalent to ≤800,000 IU/mL

PATIENT GROUPSVR
Peginterferon alfa-2A (40 kDa) plus ribavirin*Peginterferon alfa-2A (40 kDa) plus placeboInterferon alfa plus ribavirin
Overall56% (p<0.001)§29%44%
HCV genotype 146% (p<0.01)§21%36%
High viral
titer**
41%13%33%
Low viral
titer
56%39%43%
HCV genotype 2, 3 76% (p<0.01)45%61%
High viral
titer**
74%40%58%
Low viral
titer
81%58%65%